"Research-Grade CBL-514": Why No COA Can Verify It

As Caliway moved into Phase 3 in 2026 and presented data on combining CBL-514 with GLP-1 drugs, the name began to appear well outside the clinic: forum threads and low-quality websites that call it a "CBL peptide", confuse it with names such as "CBL 154", or describe it as a "research-grade agent". None of this changes the regulatory position. CBL-514 is an investigational new drug, and the only legitimate supply is through registered clinical trials run by its sponsor.

For a verification platform the question is therefore not where to find CBL-514 but whether any material offered under that name could ever be verified. The answer depends on what the sponsor has disclosed.

The pattern is typical for an investigational product: enough is disclosed for ethics committees and regulators, not enough for anyone else to reproduce it. That is the core of the verification problem.

For a research peptide, identity is a sequence. Mass spectrometry confirms the molecular mass, HPLC compares retention against a reference, and together they answer the question "is this the molecule on the label?". For CBL-514 the identity is a formulation: two active ingredients, a fixed ratio and a vehicle that makes two poorly water-soluble polyphenols injectable. A laboratory can identify and quantify curcumin and resveratrol in a vial. It cannot establish that the vial matches a specification it has never seen.

The chemistry adds further traps, each of which a competent lab report would have to address:

• Curcumin is rarely pure curcumin. Material derived from turmeric typically contains the related curcuminoids demethoxycurcumin and bisdemethoxycurcumin, which co-elute closely on HPLC and must be reported separately if the product claims curcumin specifically.
• Resveratrol has two isomers. CBL-514 specifies the trans isomer; exposure to UV light converts trans- to cis-resveratrol, so isomer content is a stability attribute, not a given.
• Both actives are pH- and light-sensitive. Curcumin degrades faster as pH rises towards neutral and alkaline values, and resveratrol degrades faster at physiological pH, which is one reason clinical material is supplied as a powder.
• A single "purity" figure is meaningless for a two-component product. A COA reporting "99% purity" for a mixture does not say which component was measured or whether the ratio is right.

Even setting the clinical specification aside, a certificate of analysis for any material sold as CBL-514 would need to report at least the following to be meaningful:

• Identity of curcumin and trans-resveratrol by two independent methods, for example HPLC-UV against reference standards plus LC-MS.
• Separate assay values for each active, so the ratio can be calculated.
• The curcuminoid profile (demethoxycurcumin, bisdemethoxycurcumin) and cis-resveratrol content as specified impurities.
• Identity and amount of any solubiliser or excipient.
• Sterility and bacterial endotoxin results, because the product is described as an injectable.
• Residual solvents from extraction or synthesis.
• Batch number, testing laboratory and a verification route back to that laboratory.

A report meeting all of these points would establish what is in the vial. It still would not establish that the contents match Caliway's investigational product, whose specification is confidential.

CBL-514 has no approval in any jurisdiction and is supplied only under investigational protocols. Labelling a product "for research use only" does not turn an unapproved drug into a lawful research chemical when it is marketed for human use; US regulators have repeatedly taken action against online sellers of unapproved drugs carrying research-use-only labels. This article describes analytical and regulatory facts and is not legal advice.

• Claims that the product is "the same as" or "equivalent to" the clinical drug – nobody outside the sponsor can verify that.
• Peptide framing ("CBL-514 peptide") for a product whose disclosed actives are polyphenols.
• A single purity percentage with no assay for each component.
• No batch-specific COA, or a COA that cannot be verified with the issuing laboratory.
• Usage instructions of any kind – a genuine research reagent does not come with them.

No. The CBL-0203 protocol names curcumin and trans-resveratrol – two small-molecule polyphenols – as its active ingredients. Calling it a peptide is a sign of unreliable sourcing.

CBL-514 is an investigational drug and is supplied only within Caliway's registered clinical trials. It has no commercial approval, and ChemVerify does not list it or any vendor offering it.

Those are its disclosed active ingredients, but the clinical product also depends on an undisclosed ratio, formulation and specification. Mixing the two compounds does not reproduce the investigational drug or its trial results.

No. "CBL 154" and similar names appear on low-quality websites and do not correspond to any registered clinical programme; the registered compound is CBL-514.

A lab can identify and quantify curcumin and resveratrol and test for contaminants. It cannot confirm equivalence to the clinical product, because the reference specification is not public.